Efficacy and Safety of Early Initiation of Vericiguat in Heart Failure After Acute Myocardial Infarction
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 200 participants.
Also called NCT06812546
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT06812546
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT06812546. Randomized; single masking; primary purpose treatment. Start 2025-04-01 (anticipated); primary completion 2026-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Early Initiation of Vericiguat in Heart Failure After Acute Myocardial Infarction
- Acronym
- VIC-MI
- Condition
- Heart Failure
- Condition
- Acute Myocardial Infarction (AMI)
- Condition
- Acute Heart Failure (AHF)
- Intervention (Drug)
- Vericiguat
- Lead sponsor
- Dongying Zhang
- Collaborator
- The Second Affiliated Hospital of Chongqing Medical University
- Collaborator
- First Affiliated Hospital of Chongqing Medical University
Record details
- Record id
cardio:ct-nct06812546- Content hash
8f02d5cf8659ceaa3ad444f323ebed4178b7264e10b4e5821975638d00fd5df9